Germline BRCA2 nonsense mutations in bladder carcinoma may reflect the pan-cancer susceptibility attributed to germline BRCA2 mutations in analysis of other adult cancers.41 Future assessment of a larger BLCA cohort may reveal associations between germline FA mutations and clinical outcomes, similar to how an expanded cohort of prostate cancer patients revealed significantly more deleterious germline mutations in DNA repair genes in patients with metastatic vs. localized prostate cancer.50 This evidence concerns the gene BRCA2 and prostate cancer.